Cargando…
CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients
BACKGROUND: Although antibody-mediated immune responses are considered pathogenic and responsible for neural injury in anti-leucine-rich glioma-inactivated protein 1 (anti-LGI1) encephalitis, previous studies have indicated that cytokines and chemokines might play roles in the pathogenic process by...
Autores principales: | Lin, You-ting, Yang, Xue, Lv, Jing-wei, Liu, Xue-wu, Wang, Sheng-jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792990/ https://www.ncbi.nlm.nih.gov/pubmed/31632040 http://dx.doi.org/10.2147/NDT.S222258 |
Ejemplares similares
-
CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Response to Letter]
por: Wang, Sheng-jun, et al.
Publicado: (2020) -
CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]
por: Wei, Mingyu, et al.
Publicado: (2020) -
Anti-leucine-rich Glioma Inactivated-1 Encephalitis Associated with Essential Thrombocythemia
por: Yuan, Xiaoling, et al.
Publicado: (2020) -
Leucine-Rich Glioma-Inactivated 1 Encephalitis: Broadening the Sphere
por: Rachdi, Amine, et al.
Publicado: (2019) -
Limbic encephalitis associated with leucine-rich glioma-inactivated 1 antibodies
por: Messelmani, Mariem, et al.
Publicado: (2015)